Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023

4,050.0013,500.00

Published September 2018

For Sample Pages email deirdre@kellysci.com

Clear

Description

Kelly Scientific analysis indicates that the global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023.

 

The majority of the market will be dominated by microbiome based therapeutics, with an estimate of over 90%, compared to less than 10% in microbiome diagnostics.

 

This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials.

 

• An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
• Global microbiome market, global breakdown, application breakdown and leading market players
• Detailed account of the microbiome industry market by geography, indication and company profiles
• Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
• Insight into the challenges faced by stakeholders
• Insight into the biobanking industry globally and its impact on the overall market
• Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota• Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
• SWOT analysis of the global market
• Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW

Key Questions Answered

• What are the Main Microbiome Therapeutics in the Pipeline?
• What are the Main Microbiome Diagnostics in the Pipeline?
• What Key Biologics are in the Pipeline?
• How Many Human Therapeutic and Diagnostic Microbiome Products are in the Pipeline?
• What is the Human Therapeutic Pipeline like by Drug, Company and Stage of Development?
• What Microbiome Therapeutics are in the Clostridium Difficile Infection Pipeline?
• Who are the Major Players in the Therapeutic and Diagnostic Spaces?
• What will the Microbiome Therapeutic Market be Worth in 2023?
• What will the Microbiome Therapeutic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
• What will the Microbiome Diagnostic Market be Worth in 2023?
• What will the Microbiome Diagnostic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?
• What are the Main Drivers, Threats and Opportunities of these Markets?
• What were the Most Influential Market Deals to Date?
• How Much Venture Capital has Been Invested in the Microbiome Industry?
• What Major Microbiome Companies have Received Investment?
• What Microbiota are Associated with Cancer Development?
• How does Gut Dysbiosis influence the Host Inflammatory Response?
• Is there an Association Between the Development of Diabetes and Our Microbiota?
• How does Clostridium difficile Infection Impact the Microbiome?
• What Host-Microbe Interactions Occur During the Pathogenesis of Dental Caries?
• During Cirrhosis of the Liver, What Brain Dysfunction Occurs Due to Gut Dysbiosis?
• What are the Main Therapeutic Intervention Strategies for Microbiome Dysbiosis
• What Safety Requirements are Needed for Microbiome Therapeutics?
• What Clinical Trials are Investigating Probiotics and Obesity?
• What Clinical Trials are Investigating Probiotics and Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease?
• What Clinical Trials are Investigating Probiotics and Irritable Bowel Syndrome?
• What Clinical Trials are Investigating Probiotics and Obesity?
• How Has the Human Microbiome Project Investigated IBD, Prediabetes and Pregnancy?
• How does the Human Microbiome Differ Between Geographical Areas and Bodily Locations?

For sample pages please email deirdre@kellysci.com

Pricings:

Single User Licence €4,500

Mid Level Licence €9,000

Enterprise Wide Licence  €13,500

Additional information

Licence Types

, , ,

You may also like…